United Therapeutics (UTHR) Other Non-Current Assets (2009 - 2026)

United Therapeutics has reported Other Non-Current Assets for 18 years, with the latest figure at $233.2 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 4.86% year-over-year to $233.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $233.2 million (up 4.86% YoY) and the FY2025 annual result came in at $196.9 million, down 11.35% from the prior year.
• Other Non-Current Assets grew to $233.2 million in Q1 2026 per UTHR's latest filing, from $196.9 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $262.6 million in Q3 2025 and troughed at $105.8 million in Q2 2022.
• A 5-year average of $170.2 million and a median of $167.9 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets plunged 40.23% in 2022, then jumped 46.31% in 2024.
• Over 5 years, Other Non-Current Assets stood at $114.3 million in 2022, then surged by 32.81% to $151.8 million in 2023, then surged by 46.31% to $222.1 million in 2024, then decreased by 11.35% to $196.9 million in 2025, then gained by 18.44% to $233.2 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $233.2 million, $196.9 million, and $262.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.